Orexo Ab Stock EBITDA

In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.

According to the company disclosure, Orexo AB reported earnings before interest,tax, depreciation and amortization of (116.3 Million). This is 113.25% lower than that of the Pharmaceuticals sector and 119.75% lower than that of the Health Care industry. The ebitda for all Sweden stocks is 102.98% higher than that of the company.

The Macroaxis Fundamental Analysis modules help investors analyze Orexo AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Orexo AB using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Orexo AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

When running Orexo AB's price analysis, check to measure Orexo AB's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Orexo AB is operating at the current time. Most of Orexo AB's value examination focuses on studying past and present price action to predict the probability of Orexo AB's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Orexo AB's price. Additionally, you may evaluate how the addition of Orexo AB to your portfolios can decrease your overall portfolio volatility.